で公開中です！ 詳しく見る
AMLXのアイコン

Amylyx Pharmaceuticals
AMLX

26.34 USD
-1.31
4.74%
終値時点 更新済み 10月16日 16:00 EDT
プレマーケット
時間外取引
26.34
0.00
0%
1日
-4.74%
5日間
-6.06%
1か月
-19.28%
3か月
54.76%
6か月
48.56%
年初来
130.65%
1年
73.63%
5年間
45.77%
10年間
45.77%
 

概要： Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company focused on developing novel therapies for communities with high unmet medical needs. The company has preclinical and clinical development programs in endocrine conditions and neurodegenerative diseases. Its pipeline includes investigational therapies matched with diseases based on mechanistic rationale, clinical outcomes, biomarkers, and preclinical data. The company is currently developing avexitide for Post-Bariatric Hypoglycemia, AMX0035 for Wolfram Syndrome, AMX0114 for Amyotrophic Lateral Sclerosis, and AMX0318 for Post-Bariatric Hypoglycemia and other rare diseases.

従業員数： 136

ヘルスケア 医薬品メーカー（スペシャリティ・ジェネリック）

ニュース

ポジティブ
ニュートラル
ネガティブ
センチメント 3か月間
ポジティブ 41.9%
ニュートラル 51.6%
ネガティブ 6.5%
ニュートラル
Schaeffers Research
4 日前
11 Stocks Most Likely to See a Short Squeeze Rally
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into earnings season.
11 Stocks Most Likely to See a Short Squeeze Rally
ニュートラル
Business Wire
10 日前
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in PBH at ObesityWeek® 2026 Annual Meeting.
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
ポジティブ
MarketBeat
14 日前
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
Amylyx Pharmaceuticals NASDAQ: AMLX said its Phase III trial of avexitide in post-bariatric hypoglycemia, or PBH, met its primary endpoint and all secondary endpoints, positioning the company to submit a New Drug Application to the U.S. Food and Drug Administration before year-end.
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
ニュートラル
Schaeffers Research
15 日前
10 Stocks With Massive Short Squeeze Potential
Bond yields, oil prices, and inflation rhetoric have teamed up to make it tough for investors heading into Q4. Where are short sellers putting their money?
10 Stocks With Massive Short Squeeze Potential
ニュートラル
Business Wire
23 日前
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum.
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
ニュートラル
Seeking Alpha
先月
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Amylyx Pharmaceuticals, Inc. (AMLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
ニュートラル
Business Wire
先月
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $AMLX--Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference.
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
ポジティブ
The Motley Fool
先月
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
Amylyx Pharmaceuticals raised $500 million to strengthen its balance sheet. A potential 2027 drug launch could provide the company's next catalyst.
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
ネガティブ
Market Watch
先月
20 stocks likely to lose money even if the bull market continues
Certain stocks are such poor bets that they are likely to lose ground even in bull markets.
20 stocks likely to lose money even if the bull market continues
ポジティブ
The Motley Fool
先月
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
Analysts also raised their price targets on the company. On top of that, it launched a new round of capital raising.
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
ニュースランキングを見る
価格チャートは Lightweight Charts™ を使用して実装されています